Tolfenamic acid in acute and prophylactic treatment of migraine: a review

• Published in: Pharmacology & toxicology Vol. 75 Suppl 2; p. 81
• Main Author: Hansen, P E
• Format: Journal Article
• Language: English
• Published: Denmark 01.01.1994
• Subjects: Acute Disease; Humans; Migraine Disorders - drug therapy; ortho-Aminobenzoates - therapeutic use; Premedication; Prostaglandin Antagonists - therapeutic use
• ISSN: 0901-9928
• DOI: 10.1111/j.1600-0773.1994.tb02005.x

The possible role of prostaglandins (PGs) in migraine has been the subject of increasing attention after the rather dramatic experiments done in man by Bergström and coworkers more than 25 years ago (1965). The role of PGs in migraine, however, is still hypothetical and not yet explained. PGs are known to sensitize nociceptors and produce hyperalgesia. PGs are involved in platelet aggregation thereby releasing serotonin. Vasodilatation, oedema and hyperalgesia in migraine have much in common with an inflammatory reaction. Tolfenamic acid (TA) inhibits PG biosynthesis and action and has an anti-aggregatory effect. TA is better than aspirin and as effective as ergotamine in treatment of acute migraine attacks. TA has fewer side effects than ergotamine. TA is as effective as propranolol in prophylactic treatment of migraine. The dose regimen of TA in acute treatment of migraine is 200 mg when the first symptoms of migraine appear. The treatment can be repeated after 2-3 hours if satisfactory effect is not obtained. The dose regimen of TA in prophylactic treatment of migraine is one sustained release tablet of 300 mg or 100 mg 3 times daily. After a treatment period of three months the regimen should be re-evaluated.